vs

Side-by-side financial comparison of VerifyMe, Inc. (VRME) and Vivos Therapeutics, Inc. (VVOS). Click either name above to swap in a different company.

VerifyMe, Inc. is the larger business by last-quarter revenue ($5.0M vs $3.8M, roughly 1.3× Vivos Therapeutics, Inc.). VerifyMe, Inc. runs the higher net margin — -66.7% vs -180.3%, a 113.6% gap on every dollar of revenue. On growth, Vivos Therapeutics, Inc. posted the faster year-over-year revenue change (3.4% vs -7.4%). Over the past eight quarters, Vivos Therapeutics, Inc.'s revenue compounded faster (5.8% CAGR vs -5.2%).

VerifyMe, Inc. is a technology provider specializing in identity verification, anti-counterfeiting, and brand protection solutions. Its offerings include secure authentication tools, supply chain traceability systems, and customer engagement platforms, serving consumer goods, pharmaceutical, and retail sectors across North America and select global markets.

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.

VRME vs VVOS — Head-to-Head

Bigger by revenue
VRME
VRME
1.3× larger
VRME
$5.0M
$3.8M
VVOS
Growing faster (revenue YoY)
VVOS
VVOS
+10.8% gap
VVOS
3.4%
-7.4%
VRME
Higher net margin
VRME
VRME
113.6% more per $
VRME
-66.7%
-180.3%
VVOS
Faster 2-yr revenue CAGR
VVOS
VVOS
Annualised
VVOS
5.8%
-5.2%
VRME

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
VRME
VRME
VVOS
VVOS
Revenue
$5.0M
$3.8M
Net Profit
$-3.4M
$-6.9M
Gross Margin
41.2%
78.1%
Operating Margin
-68.2%
-166.8%
Net Margin
-66.7%
-180.3%
Revenue YoY
-7.4%
3.4%
Net Profit YoY
-38.4%
-143.8%
EPS (diluted)
$-0.26
$-0.58

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
VRME
VRME
VVOS
VVOS
Q4 25
$3.8M
Q3 25
$5.0M
$6.8M
Q2 25
$4.5M
$3.8M
Q1 25
$4.5M
$3.0M
Q4 24
$3.7M
Q3 24
$5.4M
$3.9M
Q2 24
$5.4M
$4.1M
Q1 24
$5.8M
$3.4M
Net Profit
VRME
VRME
VVOS
VVOS
Q4 25
$-6.9M
Q3 25
$-3.4M
$-5.4M
Q2 25
$-291.0K
$-5.0M
Q1 25
$-571.0K
$-3.9M
Q4 24
$-2.8M
Q3 24
$-2.4M
$-2.6M
Q2 24
$-346.0K
$-1.9M
Q1 24
$-553.0K
$-3.8M
Gross Margin
VRME
VRME
VVOS
VVOS
Q4 25
78.1%
Q3 25
41.2%
58.0%
Q2 25
35.2%
55.2%
Q1 25
33.4%
50.0%
Q4 24
56.7%
Q3 24
34.9%
60.5%
Q2 24
39.1%
65.4%
Q1 24
39.2%
56.7%
Operating Margin
VRME
VRME
VVOS
VVOS
Q4 25
-166.8%
Q3 25
-68.2%
-69.8%
Q2 25
-7.1%
-127.4%
Q1 25
-13.3%
-129.9%
Q4 24
-75.9%
Q3 24
-52.8%
-68.5%
Q2 24
-10.0%
-47.8%
Q1 24
-11.2%
-110.7%
Net Margin
VRME
VRME
VVOS
VVOS
Q4 25
-180.3%
Q3 25
-66.7%
-79.6%
Q2 25
-6.4%
-131.2%
Q1 25
-12.8%
-128.1%
Q4 24
-76.4%
Q3 24
-44.6%
-67.8%
Q2 24
-6.5%
-47.6%
Q1 24
-9.6%
-110.1%
EPS (diluted)
VRME
VRME
VVOS
VVOS
Q4 25
$-0.58
Q3 25
$-0.26
$-0.49
Q2 25
$-0.02
$-0.55
Q1 25
$-0.05
$-0.45
Q4 24
$0.41
Q3 24
$-0.23
$-0.40
Q2 24
$-0.03
$-0.60
Q1 24
$-0.05
$-1.63

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
VRME
VRME
VVOS
VVOS
Cash + ST InvestmentsLiquidity on hand
$2.0M
Total DebtLower is stronger
$2.9M
Stockholders' EquityBook value
$11.1M
$-1.5M
Total Assets
$13.3M
$25.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
VRME
VRME
VVOS
VVOS
Q4 25
$2.0M
Q3 25
$3.1M
Q2 25
$4.4M
Q1 25
$2.3M
Q4 24
$6.3M
Q3 24
$2.6M
$6.3M
Q2 24
$2.9M
$6.9M
Q1 24
$2.8M
$2.6M
Total Debt
VRME
VRME
VVOS
VVOS
Q4 25
$2.9M
Q3 25
Q2 25
Q1 25
Q4 24
$1.2M
Q3 24
$500.0K
$1.2M
Q2 24
$600.0K
$1.2M
Q1 24
$800.0K
Stockholders' Equity
VRME
VRME
VVOS
VVOS
Q4 25
$-1.5M
Q3 25
$11.1M
$2.5M
Q2 25
$14.4M
$4.6M
Q1 25
$14.6M
$4.4M
Q4 24
$8.0M
Q3 24
$10.3M
$7.7M
Q2 24
$12.3M
$6.3M
Q1 24
$12.4M
$582.0K
Total Assets
VRME
VRME
VVOS
VVOS
Q4 25
$25.2M
Q3 25
$13.3M
$25.6M
Q2 25
$17.2M
$26.0M
Q1 25
$17.1M
$11.3M
Q4 24
$15.3M
Q3 24
$14.8M
$15.3M
Q2 24
$17.5M
$15.8M
Q1 24
$17.9M
$11.8M
Debt / Equity
VRME
VRME
VVOS
VVOS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.15×
Q3 24
0.05×
0.16×
Q2 24
0.05×
0.19×
Q1 24
0.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
VRME
VRME
VVOS
VVOS
Operating Cash FlowLast quarter
$243.0K
$-3.8M
Free Cash FlowOCF − Capex
$-5.3M
FCF MarginFCF / Revenue
-139.7%
Capex IntensityCapex / Revenue
40.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-17.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
VRME
VRME
VVOS
VVOS
Q4 25
$-3.8M
Q3 25
$243.0K
$-4.2M
Q2 25
$710.0K
$-3.5M
Q1 25
$-404.0K
$-3.8M
Q4 24
$-2.9M
Q3 24
$-10.0K
$-4.2M
Q2 24
$372.0K
$-3.0M
Q1 24
$-60.0K
$-2.5M
Free Cash Flow
VRME
VRME
VVOS
VVOS
Q4 25
$-5.3M
Q3 25
$-4.2M
Q2 25
$-4.3M
Q1 25
$-3.9M
Q4 24
$-3.1M
Q3 24
$-12.0K
$-4.4M
Q2 24
$369.0K
$-3.1M
Q1 24
$-62.0K
$-2.7M
FCF Margin
VRME
VRME
VVOS
VVOS
Q4 25
-139.7%
Q3 25
-62.6%
Q2 25
-111.6%
Q1 25
-129.9%
Q4 24
-84.0%
Q3 24
-0.2%
-113.4%
Q2 24
6.9%
-76.7%
Q1 24
-1.1%
-78.0%
Capex Intensity
VRME
VRME
VVOS
VVOS
Q4 25
40.0%
Q3 25
1.2%
Q2 25
20.2%
Q1 25
4.0%
Q4 24
4.5%
Q3 24
0.0%
5.0%
Q2 24
0.1%
1.5%
Q1 24
0.0%
4.4%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

VRME
VRME

Proactive Services$4.2M83%
Other$869.0K17%

VVOS
VVOS

Services$3.2M84%
Products$594.0K16%

Related Comparisons